Nomegestrol acetate

Nomegestrol acetate
Product Description

Specific Disclaimer. This active ingredient could be protected by a patent in force and would be therefore developed on request exclusively for the purposes stated in Article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC (Bolar provision). No activity will be performed with the active ingredients protected by a patent in force beyond the scope of the Bolar provision in any concerned jurisdiction. Nothing herein should be construed as an offer or promotion or advertisement for the sale or use of any product, if such sale or use infringes valid patents and is not authorized under applicable laws and regulations. This information is provided to you solely for your evaluation, to determine your interest in a potential relationship with Aspen Oss B.V.

Read more Show less

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Specifications
  • CAS Registry Number
    58652-20-3
  • Supplied from
    Netherlands
More specifications Fewer specifications

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile

More Products from Aspen Healthcare. We Care (58)

  • Cidofovir

    Product Cidofovir

    This API is part of the FCC product portfolio
  • Etelcalcetide

    Product Etelcalcetide

    Specific Disclaimer. This active ingredient could be protected by a patent in force and would be therefore developed on request exclusively for the purposes stated in Article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC (Bolar provision). No activity will be performed with the ac...
  • Fluphenazine Decanoate

    Product Fluphenazine Decanoate

    This API is part of the FCC product portfolio
  • Fluphenazine Hydrochloride

    Product Fluphenazine Hydrochloride

    This API is part of the FCC product portfolio
  • Levalbuterol Hydrochloride

    Product Levalbuterol Hydrochloride

    This API is part of the FCC product portfolio
  • Methazolamide

    Product Methazolamide

    This API is part of the FCC product portfolio
  • Noscapine on Resin

    Product Noscapine on Resin

    This API is part of the FCC product portfolio
  • R-Baclofen

    Product R-Baclofen

    This API is part of the FCC product portfolio
  • Ropivacaine Base

    Product Ropivacaine Base

    This API is part of the FCC product portfolio
  • S-Ropivacaine Hydrochloride

    Product S-Ropivacaine Hydrochloride

    This API is part of the FCC product portfolio
  • Scopolamine Base

    Product Scopolamine Base

    This API is part of the FCC product portfolio
  • Segesterone acetate

    Product Segesterone acetate

    Specific Disclaimer: This active ingredient could be protected by a patent in force and would be therefore developed on request exclusively for the purposes stated in Article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC (Bolar provision). No activity will be performed with the ac...
show all 58 other products

Aspen Healthcare. We Care resources (3)

  • Aspen API’s Green answer to peptide synthesis

    Sponsored Content Aspen API’s Green answer to peptide synthesis

    Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 
    5 Oct 2021
  • Aspen. Healthcare. We Care.

    Brochure Aspen. Healthcare. We Care.

    Aspen is a global specialty and branded pharmaceutical company committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.
  • CPHI Trend Report - Sustainability in Pharma

    News CPHI Trend Report - Sustainability in Pharma

    While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.
    15 Jun 2021